Latest Recruitment News

Resonance Health has reported record half-year revenue and strong progress in clinical trials, alongside promising new technology deployments set to enhance its global footprint.

Imugene Limited has reported compelling clinical trial results for its off-the-shelf CAR T therapy, azer-cel, alongside FDA validation and a strategic collaboration, while managing cash flow amid cost reductions.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Entropy Neurodynamics has successfully enrolled and dosed the first patient in its pioneering clinical trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder, while securing $6.1 million in new funding to accelerate development.

Dome Gold Mines has reported a significant construction sand resource at its Sigatoka project in Fiji and is progressing its feasibility study, supported by a proposed $7 million convertible note raise.

Harvest Technology Group reports improved first-half FY26 financials alongside strategic defense sector expansions, including new reseller agreements and NATO engagements.

Elders Limited delivered a resilient FY25 performance with 12% EBIT growth and a strategic focus on diversification and leverage reduction. The company’s Fourth Eight Point Plan drives operational optimisation and expansion across agribusiness divisions.

AnteoTech has marked significant progress in battery and life sciences sectors, highlighted by a major capital raise and strategic US partnership. The company is poised to convert promising trials into sales amid expanding market opportunities.

BlinkLab Limited has delivered strong diagnostic results in its U.S. autism pilot study, exceeding FDA performance thresholds and setting the stage for a pivotal 510(k) trial. The company also expanded its clinical trial network and nears completion of its European ADHD study.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.

RMA Global Limited has rebranded RateMyAgent to Renowned, integrating Curated Social to enhance its real estate marketing platform. The company’s strategic pivot in the US is paying off with record brokerage deals and strong revenue growth.